Rubicon's OmniPLEX amplification kits use proprietary methods for advanced library synthesis and high-yield amplification to prepare samples for sensitive and accurate PCR, microarray and next-generation sequencing analysis for use in biomedical research and clinical medicine. They have been successfully used with thousands of clinical FFPE samples with exceptional consistency, superior performance and proven sensitivity. The OmniPLEX kits are also fast, simple, and amenable to automation.
Financial details of the agreement were not disclosed.
About Rubicon Genomics
Rubicon Genomics, Inc. is a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for a variety of research and clinical testing applications. The company's core competency is the creation of more efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult clinical samples to facilitate gene-based research, drug development, diagnostics and forensics. Privately held Rubicon is located in Ann Arbor, Michigan. More information can be found at www.rubicongenomics.com.
Agendia is a leading molecular diagnostics company that develops and markets genomic-based products that improve the quality of life for cancer patients and simplify complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's tumor an
|SOURCE Rubicon Genomics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved